Necmettin AKDENİZ, Handan BİLEN, Hasan DOĞAN, Orhan ATEŞ, Nilnur EYERCİ, Sadullah KELEŞ, Eda DİYARBAKIR, Jale SELLİ, Adem KARA

4123

Effects of immunosuppressive drugs on oral mucosa in patients with Behçet?s disease: cytomorphological and cytopathological assessment

Effects of immunosuppressive drugs on oral mucosa in patients with Behçet?s disease: cytomorphological and cytopathological assessment

Background/aim: The aim of this study was to investigate cytomorphological and cytopathological changes in oral exfoliated smears collected from immunosuppressed patients with Behçet s disease (BD) using stereological methods. Materials and methods: For cytomorphometric analysis, mucosal cell smears were obtained from the buccal mucosa and the floor of the mouths of BD patients treated with immunosuppressive drugs and from healthy volunteers. All mucosal smears from the patients and the healthy volunteers were stained using the Papanicolaou method and examined cytopathologically under light microscopy and cytomorphologically via the stereological nucleator method. Results: The cytomorphological analysis revealed 3 types of mucosal cells, with numbers of particularly pink cells lower in the aphthous areas of the patients with BD compared to the healthy controls (P < 0.05). The nuclear volumes (NVs) and cytoplasmic volume (CVs) were significantly higher in the BD patients (P < 0.05), but the NV/CV ratio was higher only in the drug-use patient groups (P > 0.05). There was lower apoptotic activity in the nondrug-use patients with BD and in the immunosuppressive-taking BD patients. Conclusion: The findings suggest that quantifiably morphological and morphometric changes in oral mucosa can be detected by stereological techniques. Changes in these parameters may indicate malignant transformation in the oral mucosa.
PDF

___

  • 1. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005; 50: 297–350.
  • 2. Yazici H, Esen F. Mortality in Behçet’s syndrome. Clin Exp Rheumatol 2008; 26: 138–140.
  • 3. Yurdakul S, Yazici H. Behçet’s syndrome. Best Pract Res Clin Rheumatol 2008; 22: 793–809.
  • 4. Azizlerli G, Kose AA, Sarica R, Gul A, Tutkun IT, Kulac M, Tunç R, Urgancioğlu M, Dişçi R. Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol 2003; 42: 803–806.
  • 5. Marshall SE. Behçet’s disease. Best Pract Res Clin Rheumatol 2004; 18: 291–311.
  • 6. Muzulu SI, Walton S, Keczkes K. Colchicine therapy in Behçet’s syndrome--a report of five cases. Clin Exp Dermatol 1989; 14: 298–299.
  • 7. Rees TD. Drugs and oral disorders. Periodontol 2000 1998; 18: 21–36.
  • 8. Keles M, Tozoglu U, Unal D, Caglayan F, Uyanik A, Emre H, Cayir K, Aydinli B. Exfoliative cytology of oral mucosa in kidney transplant patients: a cytomorphometric study. Transplant Proc 2011; 43: 871–875.
  • 9. Rautemaa R, Hietanen J, Niissalo S, Pirinen S, Perheentupa J. Oral and oesophageal squamous cell carcinoma - A complication or component of autoimmune polyendocrinopathy-candidiasisectodermal dystrophy (APECED, APS-I). Oral Oncol 2007; 43: 607–613.
  • 10. Hansson BG, Rosenquist K, Antonsson A, Wennerberg J, Schildt EB, Bladström A, Andersson G. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol 2005; 125: 1337–1344.
  • 11. Kaugars GE, Silverman S Jr, Ray AK, Page DG, Abbey LM, Burns JC, Svirsky JA. The use of exfoliative cytology for the early diagnosis of oral cancers: is there a role for it in education and private practice? J Cancer Educ 1998; 13: 85–89.
  • 12. Ceccotti EL. Oral exfoliative cytology in the study of leukoplasia. Rev Asoc Odontol Argent 1991; 79: 41–42 (in Spanish).
  • 13. Cikojevic D, Gluncic I, Pesutic-Pisac V. Role of exfoliative cytology in diagnosis of laryngeal tumors. Acta Cytol 2007; 51: 767–772.
  • 14. Cowpe JG, Longmore RB, Green MW. Quantitative exfoliative cytology of abnormal oral mucosal smears. J R Soc Med 1988; 81: 509–513.
  • 15. Ogden GR, Cowpe JG, Wight AJ. Oral exfoliative cytology: review of methods of assessment. J Oral Pathol Med 1997; 26: 201–205.
  • 16. Slomiany BL, Piotrowski J, Piotrowski E, Slomiany A. Induction of buccal mucosal apoptosis with chronic alcohol ingestion. Biochem Mol Biol Int 1998; 44: 381–389.
  • 17. Dórea LT, Meireles JR, Lessa JP, Oliveira MC, de Bragança Pereira CA, Polpo de Campos A, Cerqueira Ede M. Chromosomal damage and apoptosis in exfoliated buccal cells from individuals with oral cancer. Int J Dent 2012; 2012: 457054.
  • 18. Rajkokila K, Anoop SS, Usharani M. Nuclear anomalies in exfoliated buccal epithelial cells of petrol station attendants in Tamilnadu, South India. J Med Genet Genomics 2010; 2: 18–22.
  • 19. Tolbert PE, Shy CM, Allen JW. Micronuclei and other nuclear anomalies in buccal smears - methods development. Mutat Res 1992; 271: 69–77.
  • 20. Thomas P, Holland N, Bolognesi C, Kirsch-Volders M, Bonassi S, Zeiger E, Knasmueller S, Fenech M. Buccal micronucleus cytome assay. Nat Protoc 2009; 4: 825–837.
  • 21. Honma T, Saito T, Fujioka Y. Possible role of apoptotic cells of the oral epithelium in the pathogenesis of aphthous ulceration. Oral Surg Oral Med Oral Pathol 1985; 59: 379–387.
  • 22. Hamurcu Z, Donmez-Altuntas H, Borlu M, Demirtas H, Ascioslu O. Micronucleus frequency in the oral mucosa and lymphocytes of patients with Behçet’s disease. Clin Exp Dermatol 2005; 30: 565–569.
  • 23. Singh A. Role of exfoliative cytology in oral lesions: with special reference to rule out malignancy. J Coll Med Sci Nepal 2010; 6: 29–37.
  • 24. Gundersen HJ. The nucleator. J Microsc 1988; 151: 3–21.
  • 25. Mattfeldt T, Mall G, Gharehbaghi H, Moller P. Estimation of surface area and length with the orientator. J Microsc 1990; 159: 301–317.
  • 26. Shareef BT, Ang KT, Naik VR. Qualitative and quantitative exfoliative cytology of normal oral mucosa in type 2 diabetic patients. Med Oral Pathol Oral Cir Bucal 2008; 13: E693–696.
  • 27. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161–165.
  • 28. Grinyó JM, Gil-Vernet S, Seron D, Hueso M, Fulladosa X, Cruzado JM, Moreso F, Fernandez A, Torras J, Riera L et al. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft. Nephrol Dial Transplant 1998; 13: 2601– 2604.
  • 29. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999; 106: 586–589.
  • 30. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 1998; 6: 101–109.
  • 31. Tanabe K. Calcineurin inhibitors in renal transplantation: what is the best option? Drugs 2003; 63: 1535–1548.
  • 32. Kim RD, Stein GS, Chari RS. Impact of cell swelling on proliferative signal transduction in the liver. J Cell Biochem 2001; 83: 56–69.
  • 33. Lee S. Diagnostic criteria of Behçet’s disease: problems and suggestions. Yonsei Med J 1997; 38: 365–369.
  • 34. Rokutanda R, Okada M, Yamaguchi K, Nozaki T, Deshpande GA, Kishimoto M. Infliximab for Behçet disease with aortic involvement: two novel case reports without concurrent use of immunosuppressive agents or corticosteroids. Mod Rheumatol 2013; 23: 412–413.
  • 35. Cerqueira EM, Gomes-Filho IS, Trindade S, Lopes MA, Passos JS, Machado-Santelli GM. Genetic damage in exfoliated cells from oral mucosa of individuals exposed to X-rays during panoramic dental radiographies. Mutat Res 2004; 562: 111– 117.
  • 36. Miller ML, Andringa A, Dixon K, Carty MP. Insights into UVinduced apoptosis: ultrastructure, trichrome stain and spectral imaging. Micron 2002; 33: 157–166.
  • 37. Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A. Expression of Bcl-2 in inflammatory sites from patients with active Behçet’s disease. Mediators Inflamm 1999; 8: 101–106.
  • 38. Baris YS, Yildiz L, Senturk N, Kandemir B. Fas (CD95) and bcl-2 expression in active skin lesions of Behçet’s disease. J Eur Acad Dermatol Venereol 2005; 19: 569–572.
  • 39. Kose O. Development of immunopathogenesis strategies to treat Behçet’s disease. Patholog Res Int 2012; 2012: 261989.
  • 40. Oney I, Kurnaz IA, Kurnaz ML. Cytoplasmic-to-nuclear volume ratio affects AP-1 complex formation as an indicator of cell cycle responsiveness. FEBS Lett 2005; 579: 433–440.
  • 41. Alberti S, Spadella CT, Francischone TR, Assis GF, Cestari TM, Taveira LA. Exfoliative cytology of the oral mucosa in type II diabetic patients: morphology and cytomorphometry. J Oral Pathol Med 2003; 32: 538–543.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Arşiv
Sayıdaki Diğer Makaleler

Cheronie Shely STANIS, Beng Kah SONG, Tock Hing CHUA, Yee Ling LAU, Jenarun JELIP

Eda DİYARBAKIR, Adem KARA, Sadullah KELEŞ, Jale SELLİ, Handan BİLEN, Nilnur EYERCİ, Necmettin AKDENİZ, Orhan ATEŞ, Hasan DOĞAN

Clarifying aspects of noninvasive mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease

Annia SCHREIBER, Antonio ESQUINAS

Sülen SARIOĞLU, Ülkü KÜÇÜK, Pinar ÇETİN, İsmail SARI, Ahmet Merih BİRLİK

Tamer ZEREN, Mustafa ÖZBEK, Necip KUTLU, Mahmut AKILLI

Özlem BOYBEYİ, Elem İNAL, Yasemin Dere GÜNAL, Mustafa Kemal ASLAN, Gülümser AYDIN, Tutku SOYER

Hülya Çetin SORKUN, Metin AKBULUT, Yaşar ENLİ, Emre TEPELİ, Sevgi ÖZKAN, Ergün ERDEM

Taraneh NAGHIBI, Sara MADANI, Saideh MAZLOOMZADEH, Faramarz DOBAKHTI

An experimental comparative study on classic tube thoracostomy and thoracostomy with a newly designed thorax drainage catheter

Mehmet ERGİN, Mehmet OKUMUŞ, Zerrin Defne DÜNDAR, Mahmut TOKUR

İbrahim KAYA, Deniz GÜLABİ, Murat YILMAZ, Ali BAŞ, Gültekin Sitki ÇEÇEN, Nurullah ŞENER